Antierythropoietin Antibodies in Hemodialysis Patients Treated with Recombinant Erythropoietin by unknown
Turk Neph Dial Transpl 2014; 23 (2): 125-130
125
Özgün Araştırma/Original Investigation
Antierythropoietin Antibodies in Hemodialysis Patients Treated with 
Recombinant Erythropoietin
Rekombinant Eritropoietin ile Tedavi Edilen Hemodiyaliz Hastalarında 
Antieritropoietin Antikorlar
Savaş Öztürk1
Alper Gümüş2
Vecihi memili3
muhammet emin Düz2
egemen CebeCi1
macit KOldAş2
Rümeyza KAzAnCIOğlu4
1  Haseki Training and Research Hospital, 
Department of Nephrology, 
	 İstanbul,	Turkey
2  Haseki Training and Research Hospital, 
Department of Biochemistry,
	 İstanbul,	Turkey
3  Haseki Training and Research Hospital, 
Department of Internal Medicine, 
İstanbul,	Turkey	
4	 Bezmialem	Vakif	University,	Faculty	of	
Medicine, Department of Nephrology, 
İstanbul,	Turkey
doi: 10.5262/tndt.2014.1002.08
Correspondence Address:
Savaş Öztürk
Haseki	Eğitim	ve	Araştırma	Hastanesi,	
Nefroloji	Bölümü,	İstanbul,	Turkey
Phone  : + 90 212 529 44 00
E-mail :	savasozturkdr@yahoo.com
Received : 03.12.2013
Accepted : 11.01.2014
AbstrAct
ObJeCTIVe:	Erythropoietin	resistance	is	a	serious	problem	in	patients	treated	with	recombinant	
erythropoietin.	Antierythropoietin	antibodies	are	considered	to	be	one	of	the	causes	of	this	resistance.	
mATeRIAl and meTHOdS: We investigated antierythropoietin antibodies in chronic hemodialysis 
patients	and	compared	the	results	with	healthy	controls	by	means	of	establishing	an	ELISA	method.	
A	 total	 of	 121	 chronic	 hemodialysis	 patients	 receiving	 recombinant	 erythropoietin	 were	 included	
in	 the	 study.	 The	 patients	 were	 subdivided	 according	 to	 the	 type	 of	 recombinant	 erythropoietin	
(erythropoietin-α	or	erythropoietin-β)	they	had	been	treated	with	in	the	last	six	months.	
ReSulTS:	The	absorbance	values	of	patients	were	compared	with	the	absorbance	values	of	the	control	
group	by	a	specific	and	reproducible	method.	LOD	(limit	of	detection)	and	LOQ	(limit	of	quantitation)	
values	were	also	calculated.	The	difference	in	the	absorbance	values	between	the	therapy	and	control	
groups	was	statistically	significant.
COnCluSIOn: Both	erythropoietin-α	and	erythropoietin-β	induce	production	of	antibodies	against	
erythropoietin.	Anti	rh-EPO	antibodies	may	play	a	role	in	EPO	resistance.
Key  wORdS:	 Erythropoietin,	 Erythropoiesis	 stimulating	 agents,	 Recombinant	 erythropoietin,	
Antierythropoietin antibody, Hemodialysis, Renal anemia
Öz
AmAÇ:	Eritropoietin	direnci	rekombinant	eritropoietin	ile	tedavi	edilen	hastalarda	ciddi	bir	sorundur.	
Antieritropoietin	antikorlar,	bu	direncin	nedenlerinden	biri	olarak	kabul	edilir.
GeReÇ ve yÖnTemleR:	Kronik	hemodiyaliz	hastalarında	ELISA	yöntemi	oluşturmak	suretiyle	
antieritropoietin	antikorları	araştırıldı	ve	sonuçları	sağlıklı	kontrollerle	karşılaştırıldı.	Rekombinant	
eritropoetin	alan	121	kronik	hemodiyaliz	hasta	çalışmaya	alındı.	Hastalar	bu	son	altı	ay	içinde	tedavi	
edilmiş	rekombinant	eritropoietinin	(eritropoietin	-	α	ya	da	eritropoietin	-	β	)	tipine	göre	ayrıldı	.
bulGulAR:	Hastaların	absorbans	değerleri	spesifik	ve	çoğaltılabilir	bir	yöntem	ile	kontrol	grubunun	
absorbans	değerleri	ile	karşılaştırıldı.	LOD	(saptanma	limiti)	ve	LOQ	(niceliklendirme	sınır)	değerleri	
de	hesaplandı.	Tedavi	ve	kontrol	grubu	arasında	absorbans	değerleri	farkı	istatistiksel	olarak	anlamlı	idi.
SOnuÇ:	 Hem	 eritropoietin-α	 hem	 de	 eritropoietin-β	 eritropoietine	 karşı	 antikorların	 üretimini	
başlatabilir.	Anti	rh-EPO	antikorları	EPO	direninde	rol	oynayabilir.
AnAHTAR  SÖzCüKleR:	 Eritropoietin,	 Eritropoez	 uyarıcı	 ajanlar,	 Rekombinant	 eritropoietin,	
Antieritropoietin antikor, Hemodiyaliz, Renal anemi126
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INTRODUCTION
Erythropoietin (EPO) is an erythropoiesis stimulating agent 
(ESA), composed of a glycosylated protein consisting of 165 
amino acids and four carbohydrate side chains with a molecular 
weight of 30400 DA (1). The gene responsible for the synthesis 
of EPO is localized on the 7th chromosome (2). It is synthesized 
in renal fibroblasts and secreted to the blood circulation. The 
physiological role of EPO is to increase the oxygen transport 
capacity of blood and all forms of oxygen deprivation act as 
a stimulus for EPO production (3). The erythropoietin receptor 
is placed on progenitor cells membrane at the bone marrow. 
It stimulates erythroid progenitor cells for differentiation and 
proliferation. EPO receptors have tyrosine kinase activity (4). 
The main cause of anemia observed in patients with renal 
failure is EPO deficiency and the type of anemia is normochromic 
normocytic (5). New treatment opportunities have prolonged the 
survival of chronic kidney disease (CKD) patients and anemia 
has therefore become a more serious problem. 
Recombinant human EPO (rh-EPO) a therapeutic choice 
since the late 1980’s, and has resulted in significant reduction 
of blood transfusion requirements in renal failure patients. At 
present, ESAs are routinely used as long-term treatment in 
the vast majority of patients with renal failure. Pure red cell 
aplasia (PRCA) may be observed in some patients during ESA 
treatment. This is a dilemma and a specific humoral immune 
response against rh-EPO is accused as the reason of this 
phenomenon (6). Endogenous EPO and rh-EPO have different 
patterns of glycosylation, which primarily involve the sialic 
acid composition of oligosaccharide groups. EPO-α (Johnson & 
Johnson, Manati, Puerto Rico) and EPO-β (Roche, Mannheim, 
Germany) are produced by recombinant methods and have 
slight differences in glycosylation. rh-EPO α has more sialic 
acid residues than rh-EPO-β. Endogen EPO and rh- EPO have 
different electrophoretic mobility patterns (7). 
Detection of antibodies against EPO is an important part 
of the diagnosis of PRCA. While there are several available 
tests for the detection of anti-EPO antibodies, each with its 
own advantages and disadvantages, none of these assays has 
any extra advantages to be preferred over others (8). Although 
radioimmunoprecipitation assay (RIPA) seems to be the 
most accurate test for detecting anti-EPO antibodies, it is not 
standardized and while enzyme linked immunosorbent assays 
(ELISAs) are more widely available, they appear to have lower 
sensitivity and specificity than RIPA (9, 10). 
The aim of this study was to establish an ELISA method 
for detection of anti-EPO antibodies and to compare the sera 
of patients on rh-EPO treatment with those of a healthy group. 
MATERIAL and METHOD 
Patients Groups: A total of 121 (55 females and 66 
males) hemodialysis patients were included in the study. 
Mean  duration  of  hemodialysis  was  44.28  ±  42.85  (min:  3, 
max:  216)  months.  The  CKD  etiology  was  hypertension  in 
39, diabetic nephropathy in 38, polycystic kidney disease in 3, 
nephrolithiasis in 3, pyelonephritis in 1, Alport syndrome in 1, 
familiar Mediterranean fever in 1, chronic obstructive disease in 
1 and chronic glomerulonephritis in 11 patients. The etiology of 
CKD was unknown in 23 patients. 
Patients with any kind of malignancy, autoimmune disease 
or any disease that might affect immunity or those using any 
kind of immunosuppressive drugs were excluded from the study. 
Data on the use of rh-EPO were obtained from clinical records. 
The dose of rh- EPO, 75-150 IU/kg per week, was applied 
subcutaneously according to the patients’ requirement based on 
red blood cell counts and iron metabolism parameters. 
Patients were divided into three groups according to their 
last rh-EPO type which they had been administered for the last 
six months. 
•  Group A (71 patients) treated only with rh-EPO-α
•  Group B (22 patients) treated only with rh-EPO-β
•  Group C (28 patients) treated with both rh-EPO-α and rh-
EPO-β
•  Fifteen female and 18 male healthy volunteers were selected 
as controls (Group D). They were apparently normal without 
any renal or hematological pathology. 
Sampling: Fasting peripheral blood samples were taken in the 
morning and collected into gel separator tubes and centrifuged. 
The rotor was operated for 15 minutes at room temperature and 
1500 g. The sera were stored at -20 °C for three-months.
Reactive and Chemicals: All chemicals were reagent 
grade. Uncoated ELISA plaques were obtained from Nagle 
Nuch  Company.  Antigens:  Rh-EPO-α  (Eprex)  was  obtained 
from Santa-Farma and rh- EPO-β (NeoRecormon) from Roche. 
Bovine  serum  albumin  (BSA)  was  obtained  from  Sigma 
(product  no:  A3803).  Conjugate  was  obtained  from  Sigma 
(product no: A8792) and substrate was obtained from Trinity 
Biotech Company.
Carbonate-Bicarbonate Buffer: Solution A consisting of 
Na2CO3 10.6 g/L (Merck), and solution B consisting of NaHCO3 
8.4 g/L (Merck) were prepared and 270 ml of solution A was 
mixed with 730 ml of solution B to prepare 1 liter carbonate-
bicarbonate buffer at pH 9.5 (11).
Phosphate Buffered Saline (PBS): For 1 liter buffer, NaCl 
8 g (Merck), KCl 200 mg (Merck), Na2HPO4.12H2O 4,22 g 
(Merck) KH2PO4 240 mg (baker) were dissolved in deionized 
water, the pH was adjusted into 7.4 and completed into 1 liter (12).
Wash Solution: 2% tween 20 (Merck) in PBS.
Washing Procedure: The automated ELISA plaque washer 
(ELX-50) were used to wash micro wells with the 350 ml wash 
solution and this step was repeated 5 times127
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elISA  Procedure:  We have determined optimal 
concentrations	 of	 samples	 and	 conjugate	 via	 the	 Gaetano	
Castelli	et	al	study	(8).	Step	1:	Coating	the	plaques:	Rh-EPO’s	
were	diluted	into	500	IU/ml	with	carbonate-carbonate	buffer	
and	200	ml	pipetted	into	micro	wells.	Plaques	were	incubated	
for	24	hours	at	room	temperature	and	were	washed.	Artifacts	of	
plastic	were	blocked	with	BSA	to	prevent	nonspecific	bindings.	
Coated	plaques	were	incubated	with	5	%	BSA	(200	ml	per	well)	
for	24	hours	at	room	temperature	again.	Plaques	were	ready	to	
use.	Step	2:	Applying	samples:	All	samples	(patient	and	control)	
were	diluted	1/10	with	wash	solution	and	pipetted	into	200	ml	
wells.	They	were	incubated	for	24	hours	at	room	temperature	
and	washed.	Step	3:	Applying	conjugate:	Horseradish	peroxidise	
labeled	 antihuman	 Ig	 G	 was	 used	 as	 conjugate.	 We	 diluted	
conjugate	 1/2500	 with	 PBS.	 200	 ml	 conjugate	 solution	 was	
pipetted	into	each	micro	well.	Plaques	were	incubated	for	three	
hours	at	room	temperature	and	were	washed.	Step	4:	Applying	
substrate:	Tetramethylbenzidine	(TMB)	was	used	as	substrate	
(ready	 for	 use),	 and	 pipetted	 200	 ml	 into	 each	 microwell.	
Plaques	were	incubated	30	minutes	at	room	temperature.	Step	
5:	Applying	stop	solution:	The	reaction	was	stopped	with	1.5	
N 200 ml H2SO4.	Step	6:	Reading.	The	absorbance	of	color	
appearing	at	the	end	of	the	procedure	was	read	at	450	nm	with	
the	ELX-800	ELISA	reader.
All	samples	were	studied	both	with	rh-	EPO-α	and	rh-EPO-β	
coated	plaques.
Statistics: The	obtained	data	were	evaluated	with	the	SPSS	
13	program.	In	the	absence	of	a	positive	calibrator,	we	could	not	
calculate	 concentrations	 of	 antierythropoietin	 antibodies.	 We	
used	absorbance	values	for	statistical	calculations	in	this	study.	
All	plaques	were	prepared	in	pairs	and	all	samples	were	analyzed	
twice.	The	samples	with	an	absorbance	value	difference	greater	
than	5%	between	two	analyses	were	excluded	from	the	study.
All	groups	were	compared	with	ANOVA	analysis	and	than	
we	applied	other	statistical	tests	to	determine	which	group	was	
different.	There	was	an	adequate	number	of	samples	in	group	
A	and	the	control	group	so	we	used	Student’s	t	test.	However,	
we	used	a	non	parametric	test	for	comparing	groups	B	and	C	
with	the	control	group.	We	applied	the	Bonferroni	correction	
and	selected	a	p	value	of	0.0125	for	the	four	groups.	The	95%	
confidence	interval	was	chosen	for	all	statistical	analyses.
ReSulTS
Table	I	gives	the	demographical	and	biochemical	values	of	
the	patient	and	control	groups.	The	absorbance	values	of	each	
individual	are	presented	in	Figure	1	and	2.	In	the	absence	of	
positive	external	calibrator,	we	tried	to	detect	the	possible	anti-
EPO	antibodies	positive	patients	by	calculating	LOD	and	LOQ	
values	(11,	13).
lOd:	It	is	the	detection	limit	of	any	analytical	procedure	
for	which	analysis	is	just	feasible.	A	series	of	blank	(negative)	
Table  I:	 The	 demographic	 and	 biochemical	 values	 of	 the	
patient	and	control	groups.
Patient (no=121) Control (no=33)
Age  51±17 51±14
Hemoglobin	(mg/dl) 9.7±1.41 14.74±0.99
Hematocrit	(%) 28.94±4.59 42.97±2.73
MCV	(μm³) 81.71±3.36 84.68±3.43
Creatinine	(mg/dl) 8.11±2.79 0.82±0.16
Urea	(mg/dl) 146±36 32±16
mCV:	Mean	corpuscular	volume
Figure 1: The absorbance values obtained from the rh-EPO-α coated 
plaque. The absorbance values of each sample in the groups are 
demonstrated. Calculated LOD and LOQ values are shown.
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Figure 2: The absorbance values obtained from the rh-EPO-β coated 
plaque. The absorbance values of each sample in the groups are 
demonstrated. Calculated LOD and LOQ values are shown.
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samples	 (a	 sample	 containing	 no	 analyte	 but	 with	 a	 matrix	
identical	to	the	average	sample	analyzed)	are	tested	and	the	
mean	blank	value	and	standard	deviation	(SD)	are	calculated.	
We	calculated	the	LOD	value	with	the	control	group	because	we	
know	that	anti-EPO	antibody	is	not	a	regular	parameter	detected	
in	normal	individuals.	LOD=	mean	of	absorbance	value	of	the	
control	group	+	3	SD.
lOQ: The	limit	of	quantitation	(LOQ)	or	concentration	is	
the	quantitative	result	that	can	be	reported	with	a	high	degree	of	
confidence.	LOQ	can	also	be	calculated	by	using	the	control	group	
mean	and	SD	values.	LOQ=	mean	of	absorbance	value	of	control	
group	+	10	SD.	The	scatter	of	each	patient’s	absorbance	values	
obtained	from	the	rh-EPO-α	coated	plaque	is	demonstrated	in	
Figure	1	and	Table	II	shows	the	comparison	of	group	absorbance	
values.	The	scatter	of	each	patient’s	absorbance	values	obtained	
from	the	rh-EPO-β	coated	plaque	is	demonstrated	in	Figure	2	
and	Table	III	shows	the	comparison	of	group	absorbance	values.	
The	absorbance	values	of	groups	obtained	from	the	rh-	EPO-α	
coated	plaque	were	significantly	different	(p=0.0004)	and	the	
absorbance	values	of	groups	obtained	from	rh-EPO-β	coated	
plaque	 were	 significantly	 different	 (p=0.01).	 The	 statistical	
results	as	a	whole	are	presented	in	Table	IV.
Table II: The	comparison	of	group	absorbance	values	obtained	from	the	rh-EPO	α	coated	plaque.
Group
A b c D
Mean	ABS 0.100±0.036 0.107±0.047 0.101±0.035 0.072±0.011
Minimum	ABS 0.037 0.057 0.048 0.053
Maximum	ABS 0.219 0.209 0.203 0.103
Patients	above	the	LOD	value
70
57%
9
40%
10
35%
0
0%
Patients	above	the	LOQ	value
3
4.2%
2
9%
1
3.5%
0
0%
Table III: The	comparison	of	group	absorbance	values	obtained	from	rh-EPO	β	coated	plaque.
Group
A b c D
Mean	ABS 0.075±0.022 0.111±0.067 0.078±0.027 0.073±0.015
Minimum	ABS 0.031 0.054 0.43 0.046
Maximum	ABS 0.131 0.240 0.143 0.099
Patients	above	the	LOD	value
3
2%
7
31%
4
18%
0
0%
Patients	above	the	LOQ	value
0
0%
2
9%
0
0%
0
0%
Table IV: The	obtained	results	of	statistical	analysis	for	each	group.
Group A Group b Group C
Rh-EPO	α	coated	plaques
The difference between mean 
values	is	statistically	significant	
(p<0.01)
Z=	|-2.83|>2.58
Group	B	is	different	from	the	
control	group	(p<0.01)
Z=	|-3.46|	>	3.28	Group	B	
is different from the control 
group	(p<0.001)
Rh-EPO	β	coated	plaques	
The difference between mean 
values	is	not	statistically	
significant	(p>0.05)
Z=	|-2.26|	>	1.96	Group	B	
is different from the control 
group	(p<0.05)
Z=	|0.558|	<	1.96	Group	B	is	
not different from the control 
group	(p>0.05)129
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The	 presence	 of	 anti-EPO	 antibodies	 should	 be	
verified	 by	 using	 another	 method	 of	 detection	 such	 as	
radioimmunoprecipitation	 or	 passive	 gel	 immuno	 diffusion.	
Moreover	it	is	important	to	investigate	the	immunogenic	part	
of	the	EPO	molecule.	Recently,	Mytych	et	al.	(19,	20)	tried	to	
develop more sensitive and standard methods for detection and 
standardization	anti-EPO	antibody	and	observed	different	results	
when	using	EPO-α	or	EPO-β.	Since	these	rh-EPOs	differ	only	
in	their	carbohydrate	content,	the	suspected	antibodies	should	
be	directed	against	the	carbohydrates.	This	hypothesis	should	
be	discussed	and	experimentally	addressed	using	enzymatically	
deglycosylated	EPO.	
On	the	other	hand,	there	is	no	direct	relationship	between	
the	rate	of	ESA	hyporesponsiveness	and	anti-EPO	antibodies	in	
the	literature.	In	the	study	of	Kharagjitsingh	et	al.	(21)	using	the	
serum	specimens	of	fifty-seven	patients	who	had	an	inadequate	
EPO	response,	only	two	were	positive	for	anti-EPO	antibodies.	
Similarly,	 Stoffel	 et	 al.	 (22)	 found	 out	 only	 6	 such	 patients	
among 536 hypo- and normoresponsive patients treated with 
epoetins for renal anemia. 
Schett	 et	 al.	 (23)	 have	 shown	 anti-EPO	 antibodies	 in	
autoimmune	 diseases	 such	 as	 systemic	 lupus	 erythematosus.	
Therefore, we can say not only that the foreign side chain of rh- 
EPO	induces	antibody	production	but	also	that	a	part	of	the	EPO	
peptide	chain	may	be	immunogenic.	Elliot	et	al.	(24)	isolated	
and characterized three different monoclonal and two different 
polyclonal	antibodies	against	rh-EPO	obtained	from	Chinese	
hamster	ovary	at	their	study.	
COnCluSIOn
These	 findings	 together	 with	 the	 clear	 evidence	 obtained	
in	our	experiments,	where	all	healthy	donors	had	absorbance	
values	lower	than	those	of	patients	treated	with	rh-EPO,	clearly	
indicate	 that	 an	 EPO-specific	 immune	 response	 is	 possible	
and,	more	importantly,	seems	to	be	strictly	related	to	rh-EPO	
administration.	This	shows	that	anti	rh-EPO	antibodies	may	play	
a	role	in	ESA	resistance.
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dISCuSSIOn
The	Kidney	Disease	Improving	Global	Outcomes	(KDIGO)	
2012	guidelines	for	anemia	in	chronic	kidney	disease	suggest	
that	PRCA	due	to	anti-EPO	antibodies	should	be	evaluated	in	
patients	exposed	to	at	least	eight	weeks	of	ESA	therapy	who	
develop	all	of	the	following:	1)	decline	in	hemoglobin	level	of	
>0.5	to	1.0	g/dL/week	or	transfusion	requirement	of	at	least	
1-2	 units/week	 to	 maintain	 adequate	 hemoglobin,	 2)	 normal	
leukocyte	and	thrombocyte	count,	3)	absolute	reticulocyte	count	
of	<10,000/microL	(14).	Determination	of	presence	of	anti-EPO	
antibodies	in	such	patients	is	crucial.	When	the	diagnosis	of	
PRCA	is	confirmed,	termination	of	EPO	therapy	and	initiation	
of	immunosuppressive	therapy	are	recommended	(6,	15).	The	
presented	study	indicates	that	the	absorbance	values	of	patients	
treated	 with	 rh-EPO-α	 against	 the	 plaque	 coated	 also	 with	
rh-EPO-α	 are	 higher	 than	 the	 control	 group	 and	 statistically	
significantly	different	(Table	II,	Table	IV).	Similarly,	Table	III	
and	IV	indicate	that	absorbance	values	of	the	patients	treated	
with	rh-EPO-β	against	the	plaque	coated	also	with	rh-EPO-β	
are	higher	than	the	control	group	and	statistically	significantly	
different.	Interestingly	while	group	B	gave	a	response	against	
the	rh-EPO-α	coated	plaque,	group	A	did	not	give	a	response	to	
the	rh-EPO-β	coated	plaque.	Similar	cross	reaction	to	EPO-α	
has	been	reported	in	other	studies	(9,	16).	It	is	possible	to	think	
that	rh-EPO-α	has	different	epitopes	from	rh-EPO-β	but	rh-
EP-β	has	similar	epitopes	to	rh-EPO-α.	This	knowledge	can	
be	 used	 while	 planning	 the	 EPO	 resistant	 anemic	 patient’s	
further	therapy.	Antibody	clearance	time	is	dependent	on	the	
concentration	of	antibody	in	the	circulation	and	the	half-life	
of antibody clearance is 5 days, leading to very low antibody 
concentrations	six	months	after	stopping	exposure	to	antigen	
(17,	18).	We	therefore	did	not	exclude	the	patient	who	used	both	
kind	of	rh-EPO	earlier	than	the	last	6	six	months	for	clearance	of	
possible	previous	anti-EPO	antibodies.
Table V: The	precision	of	established	test	and	calculated	
coefficient	of	variance	(CV)	values	are	represented.
negative pool Positive pool
rh-EPO-α	coated	plaque 4.5% 6.9%
rh-EPO	β	coated	plaque 4.8% 8.4%
Precision of test: For	calculating	the	coefficient	of	variance	
(CV),	we	prepared	three	serum	pools:	1.	Negative	pool:	From	
five	negative	samples.	2.	Anti	rh-EPO-α	positive	pool:	From	
two	 patients	 giving	 high	 absorbance	 values	 bigger	 than	 the	
LOQ	value	with	the	rh-EPO-α	coated	plaque.	3.	Anti	rh-EPO-β	
positive	pool:	From	two	patients	giving	high	absorbance	values	
bigger	than	the	LOQ	value	with	the	rh-EPO-β	coated	plaque.	
We	studied	each	pool	10	times	and	CV	values	were	calculated	
(Table	V).130
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